KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) FCF Margin: 2009-2025

Historic FCF Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 49.56%.

  • Halozyme Therapeutics' FCF Margin rose 1031.00% to 49.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.47%, marking a year-over-year increase of 702.00%. This contributed to the annual value of 46.13% for FY2024, which is 112.00% up from last year.
  • Per Halozyme Therapeutics' latest filing, its FCF Margin stood at 49.56% for Q3 2025, which was up 64.47% from 30.13% recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' FCF Margin peaked at 104.67% during Q3 2021, and registered a low of 23.00% during Q2 2024.
  • Over the past 3 years, Halozyme Therapeutics' median FCF Margin value was 46.62% (recorded in 2023), while the average stood at 45.80%.
  • In the last 5 years, Halozyme Therapeutics' FCF Margin spiked by 9,563bps in 2021 and then crashed by 7,183bps in 2022.
  • Over the past 5 years, Halozyme Therapeutics' FCF Margin (Quarterly) stood at 80.74% in 2021, then crashed by 3,738bps to 43.36% in 2022, then grew by 1bps to 43.37% in 2023, then soared by 1,550bps to 58.86% in 2024, then soared by 1,031bps to 49.56% in 2025.
  • Its FCF Margin was 49.56% in Q3 2025, compared to 30.13% in Q2 2025 and 57.87% in Q1 2025.